Correspondingly, CXCR4 antagonism, in combination with current anti-cancer immune checkpoint immunotherapy, targeting PD-1, for example, has recently been the subject of discussion and investigation as a therapeutic approach for clinical application (16, 38, 39). The gene discussed is CXCR4; the disease is cancer.